Skip to main content

Market Overview

Appaloosa, Senator Investment Group Push For Management Changes At Allergan

Share:
Appaloosa, Senator Investment Group Push For Management Changes At Allergan

Allergan plc (NYSE: AGN)’s board of directors fielded criticism Tuesday for diminishing share value with a “half-hearted strategic review” and for touting an arbitrary debt-reduction goal to justify acquisition pursuits.

“It is now clear that fresh thinking is absent from the current regime, thus explaining the market's complete loss of confidence in the stock,” Appaloosa and Senator Investment Group wrote in a joint letter.

Allergan's stock rose more than 2 percent to trade around $154.61 at time of publication.

What's Next

The shareholders urged Allergan to take tangible steps forward by breaking up the offices of CEO and chairman; appointing a new, external chairman or CEO; supplanting at least two board directors; and replacing management in critical segments.

Additionally, they called for executives to abandon acquisition strategies to instead focus on existing pharmaceutical and aesthetics lines.

“Prioritizing such flexibility at this time makes no sense given Allergan's undervalued equity currency, its mixed M&A record and the market's loss of confidence in the Company's ability to deploy capital for the benefit of shareholders,” the letter read. “More importantly, it will not address the Company's malaise.”

Related Links:

Allergan Looks To Sell Women's Health, Infectious Disease Businesses

Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved

 

Related Articles (AGN)

View Comments and Join the Discussion!

Posted-In: Appaloosa Senator Investment GroupNews Movers Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com